All patients
Age < 65y (younger) Age > 65y Age > 75y (older) BRAF mutant BRAF wild type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 < 5% PD-L1 > 1% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) Prior anti-CTLA4 benefit NO Prior anti-CTLA4 benefit YES stage III (locally advanced) stage IIIc stage IV (metastatic) stage M0 stage M0/M1A/M1B stage M1A stage M1B stage M1C
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - 1st line (L1), immune chekpoint inhibitors vs. immune chekpoint inhibitors, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 067 (N vs I ; all population), 2015 0.63 [0.48; 0.82]
CheckMate 067 (NI vs I ; all population), 2015 0.55 [0.42; 0.72]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.65 [0.53; 0.80]
CheckMate 069 (all population), 2015 0.74 [0.43; 1.27]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 1.44 [0.46; 4.49]
IMspire-170, 2020 1.06 [0.69; 1.62]
0.69 [0.57 ; 0.83 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, IMspire-170, 2020 6 42% 2,511 low not evaluable deaths (OS) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 0.63 [0.52; 0.76]
CheckMate 067 (NI vs I ; all population), 2015 0.52 [0.42; 0.64]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.83 [0.67; 1.03]
0.65 [0.50 ; 0.84 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 3 79% 1,890 low not evaluable PFS (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 0.53 [0.44; 0.64]
CheckMate 067 (NI vs I ; all population), 2015 0.42 [0.35; 0.51]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.79 [0.65; 0.97]
CheckMate 069 (all population), 2015 0.36 [0.23; 0.57]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 0.47 [0.10; 2.27]
0.51 [0.38 ; 0.70 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 5 83% 2,065 low not evaluable progression or deaths (PFS)detailed results CheckMate 067 (N vs I ; all population), 2015 0.57 [0.43; 0.76]
CheckMate 067 (NI vs I ; all population), 2015 0.42 [0.31; 0.57]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.74 [0.60; 0.92]
CheckMate 069 (all population), 2015 0.38 [0.23; 0.63]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 0.38 [0.15; 0.98]
CheckMate 069 (BRAF wild type), 2015 0.40 [0.23; 0.69]
IMspire-170, 2020 1.15 [0.88; 1.50]
0.56 [0.40 ; 0.78 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015, IMspire-170, 2020 7 84% 2,620 low not evaluable DCRdetailed results IMspire-170, 2020 0.91 [0.63; 1.32]
0.91 [0.63 ; 1.32 ] IMspire-170, 2020 1 0% 446 NA not evaluable objective responses (ORR)detailed results CheckMate 067 (N vs I ; all population), 2015 3.40 [2.02; 5.72]
CheckMate 067 (NI vs I ; all population), 2015 6.11 [3.59; 10.39]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.76 [1.28; 2.41]
CheckMate 069 (all population), 2015 15.08 [8.07; 28.17]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 9.82 [0.45; 212.91]
CheckMate 069 (BRAF wild type), 2015 12.96 [3.47; 48.38]
IMspire-170, 2020 0.77 [0.50; 1.17]
4.11 [1.78 ; 9.51 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015, IMspire-170, 2020 7 93% 2,620 low not evaluable objective responses (ORR) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 3.54 [2.46; 5.10]
CheckMate 067 (NI vs I ; all population), 2015 6.35 [4.38; 9.21]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.96 [4.16; 8.54]
CheckMate 069 (all population), 2015 12.20 [4.41; 33.76]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 9.80 [0.45; 211.42]
CheckMate 069 (BRAF wild type), 2015 13.00 [3.48; 48.60]
5.92 [4.15 ; 8.45 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015 6 52% 2,174 low not evaluable AE (any grade)detailed results IMspire-170, 2020 14.27 [3.34; 61.03]
14.27 [3.34 ; 61.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable AE (grade 3-4)detailed results IMspire-170, 2020 4.03 [2.70; 6.00]
4.03 [2.70 ; 6.00 ] IMspire-170, 2020 1 0% 436 NA not evaluable AE leading to death (grade 5)detailed results IMspire-170, 2020 1.39 [0.43; 4.44]
1.39 [0.43 ; 4.44 ] IMspire-170, 2020 1 0% 436 NA not evaluable TRAE (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 1.01 [0.64; 1.59]
CheckMate 067 (NI vs I ; all population), 2015 3.70 [1.95; 7.04]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.58 [1.88; 6.81]
CheckMate 069 (all population), 2015 0.75 [0.19; 2.97]
1.91 [0.84 ; 4.34 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 82% 2,014 low not evaluable TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.71 [0.49; 1.03]
CheckMate 067 (NI vs I ; all population), 2015 3.83 [2.74; 5.36]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.82 [3.41; 6.80]
CheckMate 069 (all population), 2015 3.77 [1.71; 8.31]
2.63 [1.01 ; 6.84 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 95% 2,014 low not evaluable TRAE leading to death (grade 5)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
1.00 [0.10 ; 9.59 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 3 0% 1,874 low not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 067 (N vs I ; all population), 2015 0.72 [0.45; 1.13]
CheckMate 067 (NI vs I ; all population), 2015 3.99 [2.72; 5.85]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.85 [3.25; 7.24]
CheckMate 069 (all population), 2015 4.18 [1.76; 9.91]
CheckMate 069 (BRAF wild type), 2015 3.39 [1.40; 8.19]
2.83 [1.28 ; 6.26 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF wild type), 2015 5 91% 2,122 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.52 [0.31; 0.88]
CheckMate 067 (NI vs I ; all population), 2015 2.72 [1.82; 4.06]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.10 [3.17; 8.19]
CheckMate 069 (all population), 2015 4.14 [1.59; 10.74]
2.30 [0.82 ; 6.41 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 93% 2,014 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.00 [0.07; 59.93]
CheckMate 069 (all population), 2015 0.24 [0.01; 7.31]
0.48 [0.11 ; 2.14 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.04 [0.61; 15.17]
CheckMate 069 (all population), 2015 0.24 [0.02; 2.68]
1.98 [0.57 ; 6.89 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 30% 2,014 low not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 3.99 [0.18; 88.92]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.01 [0.18; 22.24]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
1.91 [0.41 ; 8.82 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.06; 16.06]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
0.59 [0.15 ; 2.28 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Chills TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
0.49 [0.01 ; 24.92 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.12 [0.03; 0.39]
CheckMate 067 (NI vs I ; all population), 2015 1.08 [0.61; 1.93]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 9.36 [2.80; 31.26]
CheckMate 069 (all population), 2015 2.94 [0.81; 10.66]
1.35 [0.29 ; 6.37 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 89% 2,014 low not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
0.98 [0.03 ; 29.71 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 3.99 [0.18; 88.92]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.25 [0.01; 5.54]
1.00 [0.15 ; 6.76 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 3 0% 1,874 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 4.01 [0.45; 36.11]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 8.09 [0.43; 153.69]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
2.44 [0.57 ; 10.42 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.48 [0.21; 1.09]
CheckMate 067 (NI vs I ; all population), 2015 1.66 [0.90; 3.06]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.45 [1.60; 7.41]
CheckMate 069 (all population), 2015 0.98 [0.31; 3.04]
1.32 [0.58 ; 3.01 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 76% 2,014 low not evaluable Dry skin TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 1.37 [0.62; 3.04]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
1.34 [0.62 ; 2.88 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 3 0% 1,874 low not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 6.01 [0.30; 120.48]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.02 [0.31; 29.19]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
3.27 [0.80 ; 13.40 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 1.24 [0.23; 6.63]
1.24 [0.23 ; 6.63 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.20; 4.96]
CheckMate 067 (NI vs I ; all population), 2015 4.45 [1.26; 15.77]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.48 [1.26; 15.87]
CheckMate 069 (all population), 2015 5.11 [0.27; 95.65]
3.23 [1.52 ; 6.88 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 2.22 [0.77; 6.34]
2.22 [0.77 ; 6.34 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.02 [0.18; 89.49]
CheckMate 069 (all population), 2015 1.98 [0.09; 44.77]
1.80 [0.42 ; 7.77 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Hepatitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 10.08 [0.55; 185.32]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 10.15 [0.55; 186.51]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
5.06 [1.06 ; 24.09 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 15.93 [0.93; 273.74]
15.93 [0.93 ; 273.74 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 6.01 [0.30; 120.48]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.05 [0.30; 121.25]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
2.72 [0.51 ; 14.70 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.28; 3.47]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 5.06 [0.59; 43.61]
CheckMate 069 (all population), 2015 0.48 [0.07; 3.51]
0.84 [0.27 ; 2.68 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 38% 2,014 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.00 [0.07; 59.93]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
1.27 [0.21 ; 7.83 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.50 [0.25; 9.01]
CheckMate 067 (NI vs I ; all population), 2015 9.98 [2.31; 43.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.68 [1.96; 22.80]
CheckMate 069 (all population), 2015 7.32 [0.41; 131.94]
5.63 [2.53 ; 12.55 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.79 [0.21; 2.98]
CheckMate 067 (NI vs I ; all population), 2015 5.78 [2.20; 15.21]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 7.29 [2.52; 21.10]
CheckMate 069 (all population), 2015 10.83 [0.62; 189.76]
3.93 [1.32 ; 11.74 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 62% 2,014 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.17 [0.53; 2.56]
CheckMate 067 (NI vs I ; all population), 2015 3.04 [1.54; 5.98]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.60 [1.37; 4.95]
CheckMate 069 (all population), 2015 4.19 [0.51; 34.53]
2.26 [1.41 ; 3.63 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 24% 2,014 low not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.04 [0.61; 15.17]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
3.32 [1.15 ; 9.57 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.06; 16.06]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
1.22 [0.23 ; 6.34 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs I ; all population), 2015 3.53 [0.73; 17.15]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 14.30 [0.81; 253.04]
CheckMate 069 (all population), 2015 0.48 [0.03; 7.91]
1.87 [0.38 ; 9.32 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 40% 2,014 low not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs I ; all population), 2015 3.00 [0.31; 29.00]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 3.02 [0.31; 29.19]
CheckMate 069 (all population), 2015 0.98 [0.09; 11.08]
1.85 [0.55 ; 6.18 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
0.83 [0.12 ; 5.93 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 6.10 [0.73; 50.95]
CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
3.36 [0.98 ; 11.50 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 4.02 [0.18; 89.49]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
1.98 [0.46 ; 8.48 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs I ; all population), 2015 2.02 [0.68; 5.98]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 10.30 [1.31; 80.93]
CheckMate 069 (all population), 2015 5.11 [0.27; 95.65]
2.03 [0.45 ; 9.22 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 59% 2,014 low not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
0.98 [0.03 ; 29.71 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 1.48 [0.15; 14.67]
1.48 [0.15 ; 14.67 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 9.64 [0.55; 170.02]
9.64 [0.55 ; 170.02 ] CheckMate 069 (all population), 2015 1 0% 140 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 2.00 [0.07; 59.93]
1.65 [0.21 ; 12.81 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 3 0% 1,874 low not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 0.50 [0.02; 14.93]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
0.85 [0.14 ; 5.26 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs I ; all population), 2015 7.09 [0.87; 57.98]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 7.14 [0.87; 58.36]
CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
3.76 [1.11 ; 12.79 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015, CheckMate 069 (all population), 2015 4 0% 2,014 low not evaluable Weight decreased TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs N) EXPLORATORY, 2015 1.00 [0.02; 50.56]
0.60 [0.08 ; 4.66 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 067 (NI vs N) EXPLORATORY, 2015 3 0% 1,874 low not evaluable Abdominal pain AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.14; 7.03]
0.98 [0.14 ; 7.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable Anaemia AE (grade 3-4)detailed results IMspire-170, 2020 1.74 [0.50; 6.04]
1.74 [0.50 ; 6.04 ] IMspire-170, 2020 1 0% 436 NA not evaluable Arthralgia AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Asthenia AE (grade 3-4)detailed results IMspire-170, 2020 1.74 [0.50; 6.04]
1.74 [0.50 ; 6.04 ] IMspire-170, 2020 1 0% 436 NA not evaluable Constipation AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMspire-170, 2020 1.97 [0.07; 58.97]
1.97 [0.07 ; 58.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable Dermatitis acneiform AE (grade 3-4)detailed results Out of scale IMspire-170, 2020 22.68 [1.32; 388.47]
22.68 [1.32 ; 388.47 ] IMspire-170, 2020 1 0% 436 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMspire-170, 2020 4.44 [1.47; 13.42]
4.44 [1.47 ; 13.42 ] IMspire-170, 2020 1 0% 436 NA not evaluable Fatigue AE (grade 3-4)detailed results IMspire-170, 2020 1.65 [0.39; 7.00]
1.65 [0.39 ; 7.00 ] IMspire-170, 2020 1 0% 436 NA not evaluable Headache AE (grade 3-4)detailed results IMspire-170, 2020 1.97 [0.07; 58.97]
1.97 [0.07 ; 58.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable Hypertension AE (grade 3-4)detailed results IMspire-170, 2020 1.77 [0.73; 4.30]
1.77 [0.73 ; 4.30 ] IMspire-170, 2020 1 0% 436 NA not evaluable Increase AST AE (grade 3-4)detailed results IMspire-170, 2020 3.00 [0.60; 15.03]
3.00 [0.60 ; 15.03 ] IMspire-170, 2020 1 0% 436 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMspire-170, 2020 1.99 [0.49; 8.06]
1.99 [0.49 ; 8.06 ] IMspire-170, 2020 1 0% 436 NA not evaluable Increased Lipase Level AE (grade 3-4)detailed results IMspire-170, 2020 2.00 [0.59; 6.74]
2.00 [0.59 ; 6.74 ] IMspire-170, 2020 1 0% 436 NA not evaluable Nausea AE (grade 3-4)detailed results IMspire-170, 2020 10.02 [0.54; 184.60]
10.02 [0.54 ; 184.60 ] IMspire-170, 2020 1 0% 436 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.06; 15.80]
0.98 [0.06 ; 15.80 ] IMspire-170, 2020 1 0% 436 NA not evaluable Pruritus AE (grade 3-4)detailed results IMspire-170, 2020 0.98 [0.02; 49.71]
0.98 [0.02 ; 49.71 ] IMspire-170, 2020 1 0% 436 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMspire-170, 2020 6.03 [0.72; 50.50]
6.03 [0.72 ; 50.50 ] IMspire-170, 2020 1 0% 436 NA not evaluable Rash AE (grade 3-4)detailed results IMspire-170, 2020 7.83 [1.77; 34.66]
7.83 [1.77 ; 34.66 ] IMspire-170, 2020 1 0% 436 NA not evaluable Rash maculopapular AE (grade 3-4)detailed results IMspire-170, 2020 7.98 [0.42; 151.89]
7.98 [0.42 ; 151.89 ] IMspire-170, 2020 1 0% 436 NA not evaluable Sepsis AE (grade 3-4)detailed results IMspire-170, 2020 12.08 [0.67; 217.70]
12.08 [0.67 ; 217.70 ] IMspire-170, 2020 1 0% 436 NA not evaluable Vomiting AE (grade 3-4)detailed results IMspire-170, 2020 2.49 [0.48; 12.97]
2.49 [0.48 ; 12.97 ] IMspire-170, 2020 1 0% 436 NA not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-01 01:59 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 285,68,127,128
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743